• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Offer members evidence about medical technologies


It's not uncommon for bias and inaccuracies to infiltrate consumer health information and influence members' opinions about the healthcare they receive

With the array of new health technologies clamoring for attention from consumers and providers, the impact on managed care organizations can be significant as the costs associated with making wrong decisions continue to escalate. New and emerging technologies, even those approved for marketing, often have a limited evidence base with regard to their relative effectiveness and impact on clinical outcomes. Some are no more effective than competing technologies already in widespread clinical use; many are more expensive than existing options. Likewise, serious and life-threatening safety issues often don't emerge until after a new technology has been used by large numbers of patients over a longer period of time.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.